The American Soybean Association (ASA) submitted comments this week to both the U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) regarding regulations in response to advances in genetic engineering. ASA included in comments to USDA, that biotechnology is an essential tool in farmers quest to produce enough food to meet the needs of 9.7 billion people by 2050, creating the need for a clear, science-based regulatory system in the U.S. as an example and standard for regulatory systems of biotechnology internationally. While applauding USDAs efforts to reduce the burden on regulated entities, ASA expressed concern that aspects of the rule as proposed will increase the regulatory burden and stifle research and innovation. Additionally, ASAs comments to FDA cheered USDAs proposal to exclude certain genome-editing techniques from requiring pre-market approvals because they are low risk and could be found in nature or achieved through traditional breeding methods. ASA concluded its support saying, Technological advancements such as genome editing offer an additional tool to combat threats while also improving sustainability in production agriculture. Full comments to USDA and FDA can be found here and here, respectively. See the original post here: ASA Provides Input to USDA, FDA … Continue reading →

SAN ANTONIO, TEXAS--(Marketwired - June 15, 2017) - Nerium Biotechnology, Inc. ("Nerium" or the "Company") today announces that it is mailing a letter to shareholders in advance of the Company's annual meeting on June 29, 2017. The shareholder letter which is reproduced below, provides important information for shareholder consideration regarding the election of directors at the annual meeting. This is an important meeting for shareholders as the decisions made with respect to the election of the Company's board of directors will determine Nerium's future. Nerium is pleased to confirm the support of its largest shareholders for the re-election of the current board of directors (the "Board"). The shareholder letter, as well as a letter received by Nerium from Crandell Addington, a large shareholder of Nerium and CEO, Chairman and Director of Phoenix Biotechnology, will be mailed to shareholders today. A copy of the shareholder letter and other materials is available on the Company's issuer profile on SEDAR and on the Company's website http://www.nbiinvestors.com. Your Board needs your support, please vote using only the GREEN proxy FOR Dennis R. Knocke, Gustavo A. Ulloa, Jr., Richard J.G. Boxer, Michael Burke, Kerry Mitchell and Peter A. Leininger, M.D. Shareholders are encouraged to vote … Continue reading →

(CALIFORNIA) Thebirthplace of biotechnology is to receive$10 million for a pioneering precision medicine programme. It was announced this week thatthe California Initiative to Advance Precision Medicine (CIAPM) has been awarded the money from the local governments budget, a decision welcomed by theCalifornia Life Sciences Association (CLSA). Sara Radcliffe, President & CEO, CLSA, said:California Life Sciences Association (CLSA) applauds Governor Jerry Brown, California State Senate and California Assembly leaders for their strong support of life sciences innovation, as demonstrated again in this years 2017-2018 budget deal which allocates a $10 million investment in precision medicine research. California is the birthplace of biotechnology and today the states life sciences sector employs over 287,200 people working to develop innovative new medicines, technologies and therapies needed to treat and cure patients. The Californian city of San Diego ishostingtheBIO International Conventionalthe global event for biotechnology next week. It will celebrate the industrys many breakthroughs and on going impact on society.It will take place at the San Diego Convention Center between 19 and 22 June. BIO International ConventionalCalifornia Initiative to Advance Precision Medicine See the rest here: $10M for birthplace of biotechnology - Innovators Magazine … Continue reading →